Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • jpummil
    Member
    • Apr 2014
    • 85

    Using Pilon after MaSuRCA Assembly

    So, lots of good threads on using Pilon...but my question is specifically about the use of Pilon after using MaSuRCA for assembly. MaSuRCA specifically states that the unmodified, raw reads be used without any sort of manipulation:

    "IMPORTANT! Do not use third party tools to pre-process the Illumina data before providing it to MaSuRCA, unless you are absolutely sure you know exactly what the preprocessing tool does. Do not do any trimming, cleaning or error correction. This will likely deteriorate the assembly."

    Again, no problem for the assembly portion. BUT....when I move to the Pilon polishing step(s), do I want to try and use the raw reads as they are for polishing?!? Seems that, depending on how Pilon interprets that data, it might introduce some of the low quality aspects back into the assembly? Or does the mapping of the raw to the assembly to create the .bam resolve any such possibilities?
  • Gopo
    Member
    • Nov 2013
    • 41

    #2
    Personally, I would do quality and adapter trimming (and maybe error-correction) of the raw Illumina reads as MaSuRCA pretty much does this from what I understand and use the quality and adapter trimmed reads for polishing with Pilon.

    Comment

    • jpummil
      Member
      • Apr 2014
      • 85

      #3
      Kind of leaning that way for sure. I dug around a bit in the MaSuRCA documentation and have identified and located the "corrected" PE data created during assembly:

      pe.cor.fa - error corrected PE reads. The ordering of the reads is arbitrary, but the pairs are guaranteed to appear together. No quality scores

      So, the file looks more like merged PE data and is now a .fasta, though I don't know if Pilon was using the quality scores or not...

      I figure it's worth a try anyway....maybe compare it with the raw PE data and see what looks better in a Quast analysis...
      Last edited by jpummil; 10-02-2019, 06:27 AM.

      Comment

      • jpummil
        Member
        • Apr 2014
        • 85

        #4
        Haha! Well, THAT didn't work! BWA did OK with the indexing, etc...but Pilon quickly bailed:

        Suppressed: java.lang.IllegalStateException: Inappropriate call if not paired read

        I'll go back and manually quality trim and error correct the raw files.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          Yesterday, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Yesterday, 11:10 AM
        0 responses
        8 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        30 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        39 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-08-2026, 10:08 AM
        0 responses
        25 views
        0 reactions
        Last Post SEQadmin2  
        Working...